Collegium enters Phase III with DETERx oxycodone
This article was originally published in Scrip
Executive Summary
Collegium Pharmaceuticals, the private US company, is taking its lead product, a novel formulation of oxycodone, into a Phase III trial for chronic pain. The double-blind parallel group study will compare COL-003 with placebo over 12 weeks in patients with moderate-to-severe chronic lower back pain.